Optimizing COVID‐19 Candidate Therapeutics: Thinking Without Borders
Authors:
Open Access
- 25 March 2020
- journal article
- editorial
- Published by Wiley in Clinical and Translational Science
- Vol. 13 (5) , 830-834
Abstract
No abstract availableKeywords
This publication has 6 references indexed in Scilit:
- Respiratory syncytial virus-A dynamics and the effects of lumicitabine, a nucleoside viral replication inhibitor, in experimentally infected humansJournal of Antimicrobial Chemotherapy, 2018
- Interdisciplinary pharmacometrics linking oseltamivir pharmacology, influenza epidemiology and health economics to inform antiviral use in pandemicsBritish Journal of Clinical Pharmacology, 2017
- Integrating Clinical Research into Epidemic Response2017
- The FAIR Guiding Principles for scientific data management and stewardshipScientific Data, 2016
- Safety, Tolerability, and Pharmacokinetics of Intravenous Oseltamivir: Single- and Multiple-Dose Phase I Studies with Healthy VolunteersAntimicrobial Agents and Chemotherapy, 2012
- Clinical Pharmacodynamics of Linezolid in Seriously Ill Patients Treated in a Compassionate Use ProgrammeClinical Pharmacokinetics, 2003